Earnings Call Excerpt
Here’s the entire text of the prepared remarks from Biogen Idec’s (ticker: BIIB) Q3 2005 conference call. The Q&A is here. We recognize that this transcript may contain inaccuracies - if you find any, please post a comment below and we’ll incorporate your corrections. And please note: this conference call transcript is a Seeking Alpha product, so feel free to link to it but reproduction is not permitted without the explicit permission of Seeking Alpha.
Executives:
Elizabeth Woo, VP of IR
Jim Mullen, CEO
Burt Adelman, EVP of Development
Peter Kellogg, CFO and EVP
Bill Rastetter, Executive Chairman
Analysts:Elise Wang, Citigroup
Robin Karnouskis, Bear Stearns
Joel Sendek, Lazard Capital Markets
Jason Kantor, RBC
Mike King, Rodman Renshaw
Geoff Porges, Sanford Bernstein
Craig Parker, Lehman Brothers
Bill Tanner, Leerink Swann
Eric Schmidt, SG Cowen
May-Kin Ho, Goldman Sachs
Alex Hittle, A.G. Edwards
Mark Karvosky, Piper Jaffray
Kevin Peung, Morgan Stanley
Bret Holley, CIBC World MarketPresentation
Operator
Good afternoon. My name is Ramona, and I will be your conference facilitator. At this time I would like to welcome everyone to the Biogen Idec Third Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question and answer period. OPERATOR INSTRUCTIONS. I would now like to turn the call over to Ms. Elizabeth Woo, Vice President of Investor Relations.
Elizabeth Woo, VP of IR
Thank you, Ramona. Welcome to Biogen Idec's earning conference call for the third quarter 2005. Before we begin I'd urge everyone to go to the Investor Relations section of our Web site, www.biogenidec.com and printout the press release and accompanying tables. This will make it easier to follow along when our CFO, Peter Kellogg, reviews the financial results and the reconciliation to non-GAAP financial measures discussed today.
I'll start with the Safe Harbor statement. Comments made on this conference call include forward-looking statements regarding the Company's expectations regarding future financial results including the financial objectives of our recent restructuring, the potential for TYSABRI, the short and long-term growth of the Company, plans for the Company's commercial and pipeline products, and plans for external growth and pipeline growth.
Such statements are based on management's current expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. In particular, careful consideration should be given to the risks and uncertainties that are described in our earning release and in the periodic reports Biogen Idec has filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements.
- The Q&A from this call is here.
- All Biotech Stock Blog articles on Biogen.
- A list of full conference call transcripts available on the Seeking Alpha Network.
- The complete list of biotech stocks (and links to articles about them) covered by The Biotech Stock Blog.
- To read the full transcript on Seeking Alpha, click here »
